YOLFTbeta
C4 Therapeutics Inc

C4 Therapeutics Inc

CCCC · NASDAQ · Healthcare / Biotechnology

2.76USD-0.01 (-0.36%)

Price History

Full chart

Market Stats

Previous Close2.77
Open2.76
Day Range2.67 – 2.85
52-Week Range1.69 – 5.17
Volume2.54M
Market Cap372.77M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.91
Dividend Yield0.00%
Beta2.94
50-Day Avg3.70
200-Day Avg3.10

About

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration. It has strategic collaborations F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Betta Pharmaceuticals Co. Ltd., and Merck KGAA. Additionally, it has a collaboration agreement with Roche Holding AG for the development of Degrader-Antibody Conjugates for cancer treatment. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Andrew J. Hirsch M.B.A.
  • Employees104
  • Headquarters490 Arsenal Way, Watertown, MA, United States, 02472, USA
  • Websitehttps://www.c4therapeutics.com

Leadership

  • Mr. Andrew J. Hirsch M.B.A.CEO, President & Director · b. 1971
  • Dr. Kenneth C. Anderson M.D., Ph.D.Co-Founder, Independent Director & Member of Scientific Advisory Board · b. 1951
  • Ms. Kendra R. AdamsPrincipal Accounting Officer, CFO, Head of Corporate Affairs & Treasurer · b. 1977
  • Dr. Leonard M. J. Reyno M.D.Chief Medical Officer · b. 1962
  • Dr. Nathanael S. Gray Ph.D.Co-Founder & Member of Scientific Advisory Board
  • Ms. Courtney SolbergSenior Manager of Investor Relations
  • Ms. Kelly A. SchickChief People Officer · b. 1980
  • Dr. Isabel Chiu Ph.D.Senior Vice President of Strategic Alliances & Business Development
  • Dr. Christopher NasveschukSenior Vice President of Chemistry
  • Mr. Roy Pollock Ph.D.Senior Vice President of Biological Sciences

Financials

Income Statement

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue19.36M21.38M33.20M45.78M31.10M20.76M35.58M35.95M
Growth (%)-+10.42%+55.25%+37.93%-32.08%-33.25%+71.44%+1.02%
Cost of Revenue28.59M47.66M78.44M2.91M7.57M7.74M7.89M7.97M
Gross Profit-9.23M21.38M-45.24M45.78M31.10M13.02M35.58M27.97M
Gross Margin-47.66%100.00%-136.30%100.00%100.00%62.72%100.00%77.81%
Operating Expense7.16M56.83M15.20M127.92M160.63M152.05M155.20M132.46M
Operating Income-16.39M-35.45M-60.45M-82.13M-129.53M-139.03M-119.61M-104.49M
Operating Margin-84.64%-165.81%-182.10%-179.39%-416.56%-669.84%-336.15%-290.68%
EBITDA-15.12M-31.70M-58.83M-80.25M-124.28M-122.10M-103.37M-102.91M
EBITDA Margin-78.06%-148.26%-177.23%-175.29%-399.68%-588.28%-290.49%-286.29%
Net Income-15.71M-34.10M-66.33M-83.89M-128.18M-132.49M-105.32M-104.99M
Net Income Margin-81.14%-159.48%-199.83%-183.23%-412.19%-638.34%-295.96%-292.08%
R&D28.59M48.06M78.44M94.67M117.84M117.71M110.64M104.24M
R&D as % of Total Revenue147.66%224.77%236.30%206.76%378.96%567.09%310.92%289.98%
Interest Expense02.16M1.23M2.15M2.22M1.37M0-
Interest Expense % of Total Revenue0.00%10.09%3.70%4.68%7.13%6.61%0.00%-

Balance Sheet

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets146.49M118.26M400.14M506.76M430.84M376.45M349.60M359.07M
Total Liabilities226.24M230.22M119.35M117.16M141.61M130.34M133.62M102.49M
Total Equity-79.75M-111.96M280.79M389.61M289.23M246.11M215.99M256.59M
Cash36.31M90.55M181.73M76.12M29.75M126.59M55.50M74.60M
Total Debt14.48M13.75M22.92M42.88M87.15M70.98M65.76M59.98M
Net Debt-21.83M-76.80M-158.81M-33.24M57.40M-55.61M10.26M-14.62M

Cash Flow

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-16.98M55.61M-67.25M-86.97M-105.94M-106.84M-65.16M-98.69M
Investing Cash Flow36.92M-1.62M-190.50M-189.34M58.42M158.35M-51.27M-8.60M
Financing Cash Flow1.96M244.00K348.93M171.40M1.15M45.49M45.34M126.40M
Capital Expenditure2.69M1.35M650.00K1.28M5.50M1.71M180.00K607.00K
Free Cash Flow-19.67M54.27M-67.90M-88.24M-111.44M-108.55M-65.34M-99.30M
Dividends Paid--11.97M-----
FCF to OCF115.84%97.57%100.97%101.47%105.19%101.60%100.28%100.62%
Dividend Paid to FCF---17.63%-----

Earnings

Report DateSep 2, 2020Nov 12, 2020Mar 11, 2021May 13, 2021Aug 11, 2021Nov 10, 2021Feb 24, 2022May 5, 2022Aug 4, 2022Nov 3, 2022Feb 23, 2023May 4, 2023Aug 8, 2023Nov 1, 2023Feb 22, 2024May 8, 2024Aug 1, 2024Oct 31, 2024Feb 20, 2025May 7, 2025Aug 7, 2025Nov 6, 2025Feb 26, 2026May 12, 2026Aug 11, 2026Nov 5, 2026
EPS Estimate0.00-0.36-0.53-0.63-0.56-0.56-0.58-0.58-0.63-0.61-0.74-0.75-0.69-0.65-0.68-0.26-0.18-0.33-0.45-0.43-0.38-0.39-0.43-0.26-0.23-0.21
EPS Actual-0.10-0.63-0.04-0.49-0.51-0.51-0.31-0.65-0.56-0.65-0.77-0.71-0.73-0.54-0.70-0.38-0.26-0.35-0.49-0.37-0.37-0.30-0.18-0.20-0.18-
Surprise--75.00%92.45%22.22%8.93%8.93%46.55%-12.07%11.11%-6.56%-4.05%5.33%-5.80%16.92%-2.94%-46.15%-44.44%-6.06%-8.79%13.95%2.63%23.08%58.14%23.08%21.74%-
Timing-After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-Pre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap372.77M
Enterprise Value182.11M
Trailing P/E0.00
Forward P/E0.00
Price / Sales10.64
Price / Book1.53
EPS-0.91
Book Value2.01
Revenue (TTM)35.04M
Gross Profit (TTM)30.25M
EBITDA-99.45M
Profit Margin-289.44%
Operating Margin-397.88%
Return on Equity-48.14%
Return on Assets-19.25%
Shares Outstanding123.03M
Shares Float94.51M
Beta2.94
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 8 analystsTarget 13.33
  • Strong Buy
    4
  • Hold
    4

Ownership Breakdown

Institutions
103.10%
Insiders
0.84%
Retail / Other
0.00%

Top Institutional Holders

  • Morgan Stanley - Brokerage Accounts
    9.07M7.37%
  • RA Capital Management, LLC
    8.00M6.50%
  • Lynx1 Capital Management, LP
    7.33M5.96%
  • Squadron Capital Management LLC
    7.20M5.85%
  • Bain Capital Life Sciences Investors, LLC
    7.17M5.83%
  • Citadel Advisors Llc
    4.19M3.40%
  • Vanguard Capital Management, LLC
    3.86M3.14%
  • Wasatch Advisors LP
    3.52M2.86%
  • Two Sigma Investments LLC
    3.47M2.82%
  • Soleus Capital Management, L.P.
    3.38M2.75%
  • JPMorgan Chase & Co
    3.22M2.62%
  • Renaissance Technologies Corp
    2.46M2.00%
  • The Goldman Sachs Group Inc
    2.39M1.94%
  • Bank of America Corp
    2.36M1.92%
  • BlackRock Inc
    2.05M1.67%
  • SILVERARC CAPITAL MANAGEMENT, LLC
    1.91M1.55%
  • Acadian Asset Management LLC
    1.89M1.54%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    3.26M2.65%
  • iShares Russell 2000 ETF
    2.56M2.08%
  • Wasatch Ultra Growth
    2.50M2.04%